The stock of Diplomat Pharmacy Inc (NYSE:DPLO) is a huge mover today! About 823,918 shares traded hands. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 50.57% since April 8, 2016 and is downtrending. It has underperformed by 56.22% the S&P500.
The move comes after 7 months positive chart setup for the $1.01B company. It was reported on Nov, 10 by Barchart.com. We have $20.99 PT which if reached, will make NYSE:DPLO worth $404.00M more.
Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage
Out of 9 analysts covering Diplomat Pharmacy (NYSE:DPLO), 2 rate it a “Buy”, 0 “Sell”, while 7 “Hold”. This means 22% are positive. Diplomat Pharmacy has been the topic of 16 analyst reports since August 4, 2015 according to StockzIntelligence Inc. The firm has “Mkt Perform” rating given on Thursday, November 3 by Leerink Swann. On Wednesday, October 21 the stock rating was maintained by Mizuho with “Buy”. The firm has “Market Perform” rating given on Friday, June 24 by Cowen & Co. The firm has “Overweight” rating by Barclays Capital given on Wednesday, January 6. The firm has “Equal-Weight” rating given on Friday, October 2 by Morgan Stanley. The rating was initiated by UBS with “Buy” on Wednesday, October 21. The firm has “Neutral” rating by Bank of America given on Tuesday, June 7. The rating was maintained by Cowen & Co with “Market Perform” on Thursday, November 3. The rating was upgraded by Bank of America on Wednesday, October 14 to “Neutral”. On Thursday, November 3 the stock rating was downgraded by Raymond James to “Market Perform”.
According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”
Insitutional Activity: The institutional sentiment decreased to 1.43 in Q2 2016. Its down 0.22, from 1.65 in 2016Q1. The ratio worsened, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Parametric Port Assoc Llc holds 0.01% or 94,910 shares in its portfolio. Teachers Advisors has 74,642 shares for 0% of their US portfolio. Summit Creek Lc holds 216,385 shares or 1.29% of its portfolio. The New York-based Gabelli Funds Ltd Liability has invested 0.02% in Diplomat Pharmacy Inc (NYSE:DPLO). Blackrock Limited Liability Corporation has 0% invested in the company for 100,437 shares. The Florida-based State Board Of Administration Of Florida Retirement Sys has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Suntrust Banks reported 17,230 shares or 0% of all its holdings. Lord Abbett Comm Limited Com holds 0.01% or 102,299 shares in its portfolio. Ftb Advsrs Incorporated accumulated 0.01% or 1,203 shares. The New York-based Goldman Sachs Grp Inc has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Globeflex Cap Limited Partnership accumulated 0.26% or 27,503 shares. The Michigan-based Ls Advsr Llc has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Commerce Natl Bank accumulated 13,270 shares or 0.01% of the stock. Finemark Savings Bank And has 59 shares for 0% of their US portfolio. Sentinel Asset Mgmt has invested 0.18% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO).
Insider Transactions: Since August 1, 2016, the stock had 0 insider purchases, and 2 sales for $1.04 million net activity. Kaddis Atheer A sold $440,794 worth of stock.
More recent Diplomat Pharmacy Inc (NYSE:DPLO) news were published by: Fool.com which released: “Why Diplomat Pharmacy, Inc. Is Plunging Today” on November 03, 2016. Also Fool.com published the news titled: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” on October 26, 2016. Prnewswire.com‘s news article titled: “SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation …” with publication date: November 04, 2016 was also an interesting one.
DPLO Company Profile
Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.